子宮内避妊具、避妊、気分変化:注意すべきこと
1Queen's University School of Medicine, Kingston, Ontario, Canada.
まとめ
生殖ライフサイクル中のホルモン変化やホルモン療法は、女性に気分の変動や不安を引き起こす可能性があります。医療提供者は、ホルモン治療や避妊を検討している患者とこれらの潜在的な心理的影響について話し合うべきです。
科学分野:
- 生殖内分泌学
- 女性の健康
- 精神神経内分泌学
背景:
- 生殖ライフサイクル全体にわたる内因性ホルモンの変動は、女性の気分および不安レベルに影響を与える可能性がある。
- 避妊および閉経管理を含むホルモン療法は、心理的副作用と関連している。
- これらの影響は、全体的な幸福および日常機能に悪影響を与える可能性がある。
研究 の 目的:
- 内因性ホルモン変化と女性の心理的幸福との関連をレビューすること。
- ホルモン療法に関連する心理的有害作用を調査すること。
- ホルモン療法に関連する気分および不安の問題の管理について臨床医に情報を提供すること。
主な方法:
- 気分および不安に対するホルモンの影響に関する研究の文献レビュー。
- 様々なホルモン療法に関連する報告された心理的影響の分析。
- 患者カウンセリングのための臨床的考慮事項。
主要な成果:
- 生殖期間中の自然なホルモン変動は、気分障害および不安と関連している。
- ホルモン避妊薬、抑制療法、閉経治療は、易怒性、うつ病、不安を引き起こす可能性がある。
- 患者が報告した結果は、心理的許容性の重要性を強調している。
結論:
- 臨床医は、内因性ホルモン変化を経験している女性における潜在的な気分および不安症状に積極的に対処する必要がある。
- 医療提供者は、ホルモン療法に関連する心理的リスクについて患者にカウンセリングすべきである。
- 有効性、安全性、および許容性に関する十分な情報に基づいた議論は、ホルモン療法における共同意思決定にとって極めて重要である。
関連する概念動画
Intrauterine Drug Delivery Systems
55
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
55
Birth Control Methods
7.0K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
7.0K
Hormonal Regulation of the Menstrual Cycle
1.8K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.8K
Disorders of the Female Reproductive System
4.6K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.6K
Drugs for Treatment of Constipation-Predominant IBS
981
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
981
Ovarian Cycle
4.6K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.6K


